Biovest terminates NCI agreement, expands into Eastern Europe

By Elaine Rigoli

Tampa, Fla., Sept. 26 - Biovest International, Inc. said it decided to relocate the remaining trial-related functions currently performed at the National Cancer Institute (NCI) to non-governmental commercial facilities outside of the NCI.

The company said it expanded the number of U.S. clinical sites for its ongoing phase 3 clinical trial for BiovaxID from five sites when the Investigational New Drug application was held by the NCI to 17 U.S.-based clinical sites.

Additionally, the company opened 10 qualified sites in Eastern Europe and anticipates additional Eastern European sites to become active within about 45 days.

Moreover, the company is opening this trial to patients treated with CHOP-R (Rituxan).

The Worcester, Mass., biotechnology company said the relocation of such trial functions away from the NCI will facilitate the company's plans to expedite the trial including its expansion to additional international clinical trial sites in Eastern Europe and will provide greater control over the ongoing pathology laboratory functions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.